Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
- 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise...
DELAYED AGAIN! Will Marijuana Rescheduling Survive Constitutional Challenges, Treaty Conflicts, and Federal Court Scrutiny?